Aldona Kowalska1,2, Agnieszka Walczyk1, Artur Kowalik3,4, Iwona Pałyga1, Danuta Gąsior-Perczak1, Tomasz Trybek1, Janusz Kopczyński5, Maciej Kajor6, Estera Mikina1, Monika Szymonek1, Klaudia Gadawska-Juszczyk1, Dorota Szyska-Skrobot1, Katarzyna Lizis-Kolus1, Stefan Hurej1, Magdalena Chrapek7, Małgorzata Chłopek3, Stanisław Góźdź2,8. 1. Departments of Endocrinology, Holycross Cancer Centre, Kielce, Poland. 2. The Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland. 3. Departments of Molecular Diagnostics, Holycross Cancer Centre, Kielce, Poland. 4. Department of Surgery and Surgical Nursing with the Scientific Research Laboratory, The Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland. 5. Departments of Surgical Pathology, Holycross Cancer Centre, Kielce, Poland. 6. Department of Surgical Pathology, Medical University of Silesia, Katowice, Poland. 7. Department of Probability Theory and Statistics Institute of Mathematics, Faculty of Mathematics and Natural Science, Jan Kochanowski University, Kielce, Poland. 8. Departments of Clinical Oncology, Holycross Cancer Centre, Kielce, Poland.
Abstract
OBJECTIVE: A dynamic risk stratification with modified initial estimated risk based on response to therapy and disease course is one of the crucial changes adopted recently by the American Thyroid Association (ATA). This approach focuses on an individualized risk-adapted approach to the management of differentiated thyroid cancer. The BRAF V600E mutation is the most common genetic alteration in papillary thyroid cancer (PTC). However, the prognostic value of this mutation remains unclear. The aim of this study was to examine the relation between the BRAF V600E status in PTC and all ATA response-to-therapy categories, as well as the recurrence and persistence of both biochemical disease and structural disease. PATIENTS: Unselected PTC cases with known BRAF status diagnosed from 2000 to 2013 and actively monitored at one institution (n=723) were reviewed retrospectively. The association between the BRAF V600E mutation and clinicopathological characteristics, ATA 2015 response-to-therapy category, recurrence after a period of no evidence of disease (NED) and persistent biochemical or structural disease, was analysed. RESULTS: BRAF V600E was found in 65.7% (475/723) of PTC cases. Although BRAF mutation status correlated significantly with certain clinicopathological prognostic factors, there was no correlation with any of the response-to-therapy categories. Recurrences and persistent biochemical or structural disease were not associated with BRAF status. CONCLUSIONS: Our data are consistent with those of other studies reporting a positive relation between BRAF V600E mutation and poor prognostic factors in PTC; however, the BRAF status did not significantly correlate with a response to therapy.
OBJECTIVE: A dynamic risk stratification with modified initial estimated risk based on response to therapy and disease course is one of the crucial changes adopted recently by the American Thyroid Association (ATA). This approach focuses on an individualized risk-adapted approach to the management of differentiated thyroid cancer. The BRAFV600E mutation is the most common genetic alteration in papillary thyroid cancer (PTC). However, the prognostic value of this mutation remains unclear. The aim of this study was to examine the relation between the BRAFV600E status in PTC and all ATA response-to-therapy categories, as well as the recurrence and persistence of both biochemical disease and structural disease. PATIENTS: Unselected PTC cases with known BRAF status diagnosed from 2000 to 2013 and actively monitored at one institution (n=723) were reviewed retrospectively. The association between the BRAFV600E mutation and clinicopathological characteristics, ATA 2015 response-to-therapy category, recurrence after a period of no evidence of disease (NED) and persistent biochemical or structural disease, was analysed. RESULTS:BRAFV600E was found in 65.7% (475/723) of PTC cases. Although BRAF mutation status correlated significantly with certain clinicopathological prognostic factors, there was no correlation with any of the response-to-therapy categories. Recurrences and persistent biochemical or structural disease were not associated with BRAF status. CONCLUSIONS: Our data are consistent with those of other studies reporting a positive relation between BRAFV600E mutation and poor prognostic factors in PTC; however, the BRAF status did not significantly correlate with a response to therapy.
Authors: Danuta Gąsior-Perczak; Artur Kowalik; Agnieszka Walczyk; Monika Siołek; Krzysztof Gruszczyński; Iwona Pałyga; Estera Mikina; Tomasz Trybek; Janusz Kopczyński; Ryszard Mężyk; Stanisław Góźdź; Aldona Kowalska Journal: Cancers (Basel) Date: 2019-11-07 Impact factor: 6.639
Authors: Danuta Gąsior-Perczak; Iwona Pałyga; Monika Szymonek; Artur Kowalik; Agnieszka Walczyk; Janusz Kopczyński; Katarzyna Lizis-Kolus; Tomasz Trybek; Estera Mikina; Dorota Szyska-Skrobot; Klaudia Gadawska-Juszczyk; Stefan Hurej; Artur Szczodry; Anna Słuszniak; Janusz Słuszniak; Ryszard Mężyk; Stanisław Góźdź; Aldona Kowalska Journal: PLoS One Date: 2018-10-01 Impact factor: 3.240